Sells cancer medicines for blood and solid tumors to hospitals, pharmacies and other health care providers.
10-K for FY2025, filed Feb 26, 2026Our hematology franchise is led by BRUKINSA, which is supported by a broad clinical program with over 7,900 patients enrolled in more than…View ↗
Our solid tumor franchise is led by our anti-PD-1 monoclonal antibody, TEVIMBRA, which is currently approved in the U.S., EU, China and…View ↗
In the U.S., the Company distributes its products through specialty pharmacies and specialty distributors. The specialty pharmacies and…View ↗
Product sales account for 99% of revenue; the company sells medicines to distributors, pharmacies and hospitals, earning revenue when products are delivered and customers pay afterward.
10-K for FY2025, filed Feb 26, 2026
$5.3B
10-K for FY2025, filed Feb 26, 2026
$5.3B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product revenue, net
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
99%
FY2022: 89%
|
Product revenue, net, FY2025
$5.3B Sources
|
Sold outright |
|
Other revenue
|
1.1%
FY2022: 11%
|
Other revenue, FY2025
$61M Sources
|
In the U.S., specialty pharmacies and distributors buy medicines for resale to health care providers and patients; in Europe, sales go through distributors or directly to hospitals. In China, distributors buy products and resell them to hospitals or pharmacies.
10-K for FY2025, filed Feb 26, 2026In the U.S., the Company distributes its products through specialty pharmacies and specialty distributors. The specialty pharmacies and…View ↗
Yes. It kept 5 cents of every revenue dollar as net income in FY2025 and turned 18 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 5, 2026
$384.7MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
8-K, filed May 15, 2026
On May 13, 2026, BeOne Medicines Ltd. announced that BEQALZI™ (sonrotoclax) has received accelerated approval from the U.S. Food and Drug…View ↗
Growing. Revenue grew 4.5x in 4 years, from $1.2B in FY2021 to $5.3B in FY2025, about 46% a year.
An additional approved medicine
The older report described BRUKINSA, tislelizumab and pamiparib as approved in-house medicines; the latest reports sonrotoclax’s first approval, expanding the commercial portfolio.
10-K for FY2022, filed Feb 27, 2023 10-K for FY2025, filed Feb 26, 2026We currently have three approved medicines that were discovered and developed in our own labs, including BRUKINSA®, a small molecule…View ↗
Sonrotoclax is a potentially best-in-class BCL2 inhibitor designed to have greater potency and selectivity, and potential for better…View ↗
Broader commercial rights The older report listed tislelizumab commercial rights outside North America, Japan, the EU and certain European markets; the latest lists global commercial rights for TEVIMBRA.
Competes with AbbVie, Janssen, AstraZeneca, Eli Lilly, Innocare, Merck, Bristol Myers Squibb, Roche, Merck KGaA, Regeneron, Sanofi, GSK, Junshi, Henlius, Ascentage Pharma, and Nurix Therapeutics
10-K for FY2025, filed Feb 26, 2026AbbVie & JanssenView ↗
Loading...